Attached files

file filename
EX-31.1 - EXHIBIT 31.1 - CUMBERLAND PHARMACEUTICALS INCa2014-10kxexhibit311.htm
EX-31.2 - EXHIBIT 31.2 - CUMBERLAND PHARMACEUTICALS INCa2014-10kxexhibit312.htm
EX-10.12 - EXHIBIT 10.12 - CUMBERLAND PHARMACEUTICALS INCa2014-10kxexhibit1012marti.htm
EX-10.15 - EXHIBIT 10.15 - CUMBERLAND PHARMACEUTICALS INCa2014-10kxexhibit1015jimhe.htm
EX-10.14 - EXHIBIT 10.14 - CUMBERLAND PHARMACEUTICALS INCa2014-10kxexhibit1014rickg.htm
EX-10.11 - EXHIBIT 10.11 - CUMBERLAND PHARMACEUTICALS INCa2014-10kxexhibit1011ajkaz.htm
EX-10.13 - EXHIBIT 10.13 - CUMBERLAND PHARMACEUTICALS INCa2014-10kxexhibit1013leopa.htm
EXCEL - IDEA: XBRL DOCUMENT - CUMBERLAND PHARMACEUTICALS INCFinancial_Report.xls
10-K - 10-K - CUMBERLAND PHARMACEUTICALS INCa2014-10k.htm
EX-32.1 - EXHIBIT 32.1 - CUMBERLAND PHARMACEUTICALS INCa2014-10kxexhibit321.htm
Exhibit 23.1

Consent of Independent Registered Public Accounting Firm
The Board of Directors
Cumberland Pharmaceuticals Inc.:

We consent to the incorporation by reference in the registration statement No. 333-164376 on Form S-8 and No. 333-184091 on Form S-3 of Cumberland Pharmaceuticals Inc. of our reports dated March 9, 2015, with respect to the consolidated balance sheets of Cumberland Pharmaceuticals Inc. and subsidiaries as of December 31, 2014 and 2013, and the related consolidated statements of operations and comprehensive income (loss), equity, and cash flows for each of the years in the three-year period ended December 31, 2014, the related financial statement schedule, and the effectiveness of internal control over financial reporting as of December 31, 2014, which reports appear in the December 31, 2014 annual report on Form 10-K of Cumberland Pharmaceuticals Inc.


/s/ KPMG LLP

Nashville, Tennessee
March 9, 2015